Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat2
HCM Share
Trades60
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
HCM Company
Research
HCM Company
Timeline
Hutchmed Information
Share Price Information for Hutchmed (HCM)
Share Price is delayed by 15 minutes
Get Live Data
170.50
5.75 (3.49%)
Bid:
168.00
Ask:
172.00
Spread:
4.00 (2.381%)
Market Cap:
£1.47b
Last checked at -
Last checked at 
Intraday Hutchmed Share Chart
Hutchmed News
20 Jan 2020
Hutchison Chi-Med upbeat on progress with surufatinib
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 piv...
20 Jan 2020
Hutchinson China Reports Early Success Of Surufatinib Phase III Study
Hutchinson China Reports Early Success Of Surufatinib Phase III Study
13 Jan 2020
Hutchison China Starts Phase II Study For Cancer Treatment In China
Hutchison China Starts Phase II Study For Cancer Treatment In China
20 Dec 2019
Hutchison Chi-Med gets priority review for 'surufatinib' in China
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Adminis...
20 Dec 2019
Hutchison China Hails "Positive Step" For Cancer Treatment In China
Hutchison China Hails "Positive Step" For Cancer Treatment In China
28 Nov 2019
Hutchison China MediTech's Cancer Treatment Joins Key China State List
Hutchison China MediTech's Cancer Treatment Joins Key China State List
25 Nov 2019
Hutchison China MediTech Gets Orphan Designation For Surufatinib
Hutchison China MediTech Gets Orphan Designation For Surufatinib
12 Nov 2019
CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review
CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review
Follow the stocks
